TY - JOUR
T1 - Mucins and associated O-glycans based immunoprofile for stratification of colorectal polyps
T2 - Clinical implication for improved colon surveillance
AU - Krishn, Shiv Ram
AU - Kaur, Sukhwinder
AU - Sheinin, Yuri M.
AU - Smith, Lynette M.
AU - Gautam, Shailendra K.
AU - Patel, Asish
AU - Jain, Maneesh
AU - Juvvigunta, Vasthala
AU - Pai, Priya
AU - Lazenby, Audrey J.
AU - Roy, Hemant K.
AU - Batra, Surinder K.
N1 - Funding Information:
We would like to thank Dr. Sandra J. Gendler at Mayo Clinic, USA for anti-MUC1 antibody (HMFG2), Dr. Henrick Clausen of the University of Copenhagen, Sweden and Dr. Michael A. Hollingsworth from University of Nebraska Medical Center for providing with the anti-Tn/STn on MUC1 antibody (5E5). We would also like to thank Kavita Mallya (UNMC) for technical support. This work was supported, in parts, by the grants from National Institutes of Health (Cancer Center Support Grant P30 CA036727, EDRN CA111294, SPORE P50 CA127297, RO1 CA195586, RO1 CA183459 and U54 CA163120).
PY - 2017
Y1 - 2017
N2 - Sessile serrated adenoma/polyps (SSA/P) are premalignant lesions of colorectal cancer that are difficult to distinguish histologically from hyperplastic polyps (HP) of minimal to no malignant potential. Specific markers for differentiating SSA/P from HP can aid clinicians for optimizing colon surveillance intervals. The present study investigates the potential of mucins and associated O-glycans to distinguish SSA/P from HP. Expression of colonic mucins (MUC1, MUC4, MUC17, MUC2, and MUC5AC) and O-glycans [Sialyl LewisA (CA19-9) and Tn/Sialyl-Tn on MUC1] were analyzed in HP (n=33), SSA/P (n=39), and tubular adenoma (TA) (n=36) samples by immunohistochemistry. A significantly reduced expression of MUC4 (p=0.0066), elevated expression of MUC17 (p=0.0002), and MUC5AC (p < 0.0001) was observed in SSA/P cases in comparison to HP cases. Interestingly, significantly higher number of SSA/P cases (p < 0.0001) exhibited MUC5AC expression in the goblet cells as well as filled the crypt lumen compared to only goblet cells in majority of the HP cases. Improved diagnostic potential was revealed by multivariate logistic regression analysis where combinatorial panel of MUC5AC/MUC17 discriminated SSA/P from HP (SN/SP=85/82%). Finally, the decision tree model based marker panel (CA19-9/ MUC17/MUC5AC) predicted HP, SSA/P and TA with SN/SP of 58%/95%, 79%/90% and 97%/83%, respectively. Overall, the mucin and associated O-glycan based panel defined in the present study could aid in discriminating SSA/P from HP to devise better colon surveillance strategies.
AB - Sessile serrated adenoma/polyps (SSA/P) are premalignant lesions of colorectal cancer that are difficult to distinguish histologically from hyperplastic polyps (HP) of minimal to no malignant potential. Specific markers for differentiating SSA/P from HP can aid clinicians for optimizing colon surveillance intervals. The present study investigates the potential of mucins and associated O-glycans to distinguish SSA/P from HP. Expression of colonic mucins (MUC1, MUC4, MUC17, MUC2, and MUC5AC) and O-glycans [Sialyl LewisA (CA19-9) and Tn/Sialyl-Tn on MUC1] were analyzed in HP (n=33), SSA/P (n=39), and tubular adenoma (TA) (n=36) samples by immunohistochemistry. A significantly reduced expression of MUC4 (p=0.0066), elevated expression of MUC17 (p=0.0002), and MUC5AC (p < 0.0001) was observed in SSA/P cases in comparison to HP cases. Interestingly, significantly higher number of SSA/P cases (p < 0.0001) exhibited MUC5AC expression in the goblet cells as well as filled the crypt lumen compared to only goblet cells in majority of the HP cases. Improved diagnostic potential was revealed by multivariate logistic regression analysis where combinatorial panel of MUC5AC/MUC17 discriminated SSA/P from HP (SN/SP=85/82%). Finally, the decision tree model based marker panel (CA19-9/ MUC17/MUC5AC) predicted HP, SSA/P and TA with SN/SP of 58%/95%, 79%/90% and 97%/83%, respectively. Overall, the mucin and associated O-glycan based panel defined in the present study could aid in discriminating SSA/P from HP to devise better colon surveillance strategies.
KW - Hyperplastic polyps
KW - Mucins
KW - O-glycans
KW - Sessile serrated adenoma/polyps
KW - Tubular adenomas
UR - http://www.scopus.com/inward/record.url?scp=85010748415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010748415&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.12347
DO - 10.18632/oncotarget.12347
M3 - Article
C2 - 27705923
AN - SCOPUS:85010748415
SN - 1949-2553
VL - 8
SP - 7025
EP - 7038
JO - Oncotarget
JF - Oncotarget
IS - 4
ER -